Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $128
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a Buy rating on Abbott Laboratories (ABT) and increased the price target from $126 to $128.
April 03, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Abbott Laboratories and raised the price target from $126 to $128.
The upgrade in the price target by Citigroup reflects a positive outlook on Abbott Laboratories, likely due to strong performance or favorable market conditions. This endorsement from a major financial institution could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100